RU95107986A - Method of correction of the secondary immunodeficiency in having suffered persons with the combined abdomen trauma - Google Patents

Abstract

FIELD: medicine, immunology. SUBSTANCE: method involves continuous intravenous drop administration of "Mafusol" solution at amount 1200-1600 ml/24 h during and at the postoperative period. Dalargin solution (0.001 g/1 ml sodium chloride saline solution) is administrated intravenously, once per 24 h, at dose 100-200 mcg/kg mass. Triiodothyronine in 100 ml sodium chloride saline solution is administrated once per 24 h at dose 1-3 mcg/kg mass by intestinal probe. Preparations were administrated for 6-10 days up to normalization of adenylic and cyclic nucleotide indices, cellular and humoral immunity links, intoxication indices and others. Method provides effective correction of the secondary immunodeficiency, decreases suppurative complications by 23.3% and lethality by 20.7%. EFFECT: enhanced effectiveness of correction.

Claims (1)

The method was used to comprehensively treat victims with combined abdominal trauma by correcting secondary immunodeficiency. The method is as follows: for victims of combined abdominal trauma during the operation and in the postoperative period, the solution “Methusol” is constantly drip intravenously in the amount of 1200 - 1600 ml / day. A dalargin solution prepared ex tempore by dissolving the lyophilized powder in ampoules or vials (0.001 g) in 1 ml of an isotonic sodium chloride solution is administered intravenously once a day at 100-200 μg / kg of body weight. Triiodothyronine, crushed in powder form and mixed with 100 ml of an isotonic sodium chloride solution, is administered once per day at 1-3 mg / kg of mass into an intestinal probe performed during surgery. Drugs are administered within 6 to 10 days until the normalization of adenyl and cyclic nucleotides, cellular and humoral immunity, intoxication, and improvement of the patient’s condition. The method provides effective correction of secondary immunodeficiency, reduces the number of purulent complications by 23.3%, reduces mortality by 20.7%, bed-day - by 15.5.